A GP training intervention to reduce benzodiazepine prescription in primary care

Phase 4

Completed

• Conditions: Benzodiazepine consumption; Mental and Behavioural Disorders

• Registration Number: ISRCTN28272199
• Lead Sponsor: Primary Care Management of Mallorca (Gerencia de Atención Primaria de Mallorca)

Brief Summary

2019 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/30705235 protocol (added 16/01/2020) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35522626/ (added 09/05/2022) 2021 Results article in https://doi.org/10.3390/ijerph18157964 (added 10/05/2024)

Detailed Description

Not available

Study Timeline

• Study Start: 2016-04-06
• Study Completion: 2018-12-31
• Last Update Posted: 21 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 700

Inclusion Criteria

All GPs from the health centers where the trials will be implemented

Exclusion Criteria

Unwillingness to participate

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Total GP Doses per 1000 Habitants per Day (DHD) of benzodiazepine at 12 months

Secondary Outcome Measures

Name	Time	Method
1. Percentage of total long term benzodiazepine users at 12 months, measured via information about patient prescribed benzodiacepine for a period longer than six months registered in the prescription database of the electronic health records <br>2. Percentage of patient older than 65 long term benzodizepine users at 12 months, measured via information about patient older than 65 with a prescription of benzodiazepine registered in the prescription database of the electronic health records <br>3. Feasibility, adoption and fidelity of the intervention will be measured by an ad hoc questionnaire to measure GP opinion